Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Intepirdine

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Intepirdine
Clinical data
Other namesSB-742457, RVT-101
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • Investigational/abandoned
Identifiers
  • 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.158.094Edit this at Wikidata
Chemical and physical data
FormulaC19H19N3O2S
Molar mass353.44 g·mol−1
3D model (JSmol)
  • C3CNCCN3c1cccc(c1nc4)cc4S(=O)(=O)c2ccccc2
  • InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2 ☒N
  • Key:JJZFWROHYSMCMU-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Intepirdine (INN; developmental codesSB-742457,RVT-101)[1] is aselective5-HT6 receptorantagonist with potentialcognition,memory, andlearning-enhancing effects.[2][3] It was under development byGlaxoSmithKline for the treatment ofAlzheimer's disease and demonstrated some preliminary efficacy inphase IIclinical trials.[3] GSK chose not to continue development and sold the rights toAxovant Sciences for $5 million in December 2014.[4]

Results of aphase III clinical trial for the treatment of Alzheimer's disease were reported in September 2017.[5] The trial showed no improvement over control group and Axovant lost 70% of its value upon the announcement of the trial results.[6]

Intepirdine also entered clinical trials fordementia with Lewy bodies, also with negative results.[7] Consequently, Axovant announced in 2018 that it has discontinueddevelopment of this drug.[7]

References

[edit]
  1. ^"Intepirdine - Axovant Sciences / GlaxoSmithKline". AdisInsight. Retrieved9 January 2018.
  2. ^Upton N, Chuang TT, Hunter AJ, Virley DJ (July 2008)."5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease".Neurotherapeutics.5 (3):458–69.doi:10.1016/j.nurt.2008.05.008.PMC 5084247.PMID 18625457.
  3. ^abRossé G, Schaffhauser H (February 2010). "5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment".Current Topics in Medicinal Chemistry.10 (2):207–21.doi:10.2174/156802610790411036.PMID 20166958.
  4. ^Lowe, Derek (12 May 2015)."An Alzheimer's IPO, Because Why Not".In the Pipeline.
  5. ^Fiore, Kristina (27 September 2016)."NeuroBreak: Alzheimer's Drug Bombs; Elephant Tranquilizer ODs".MedPage Today.
  6. ^Garde, Damian (26 September 2017)."Another Alzheimer's failure: Axovant's drug flops in late-stage trial".STAT.
  7. ^abTaylor, Phil (Jan 8, 2018)."Axovant slumps as it dumps lead drug intepirdine". Fierce Biotech.
Psychoanaleptics: Anti-dementia agents (ATC codeN06D and others)
AChE inhibitor medications
Other medications
ExperimentalBACE inhibitors
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=Intepirdine&oldid=1166940594"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp